This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain and Northern Ireland. IBRANCE® (palbociclib) Prescribing Information for Great Britain and Northern Ireland click here.  Adverse event reporting information can be found at the bottom of the page.

Clinical Trials

Confidence in a Treatment that’s setting the standard3-5​​​​​​​

The efficacy and safety of IBRANCE® has been evaluated in two large Randomised Control Trials (RCTs) in women with HR+/HER2- metastatic Breast Cancer (mBC) as part of Pfizer’s robust PALOMA Clinical Trial Programme in Breast Cancer.1-5​
​​​​​​​​​​​​​

PALOMA Clinical Trials Programme

PALOMA-2 Trial

IBRANCE® + Aromatase Inhibitor (AI) PALOMA-2 Clinical Trial results including efficacy and safety outcomes.

Learn more

PALOMA-3 Trial

IBRANCE® + Fulvestrant (FUL)  PALOMA-3 Clinical Trial results including efficacy and safety outcomes.

Learn more

IBRANCE® Real World Evidence

Real World Evidence (RWE) for IBRANCE® (pabociclib) in advanced breast cancer

Learn more

IBRANCE® Safety Profile

IBRANCE® safety information and frequent adverse events

View
AI : Aromatase Inhibitor, ER+ / HER2− : Oestrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative, ET : Endocrine Therapy, HR+ / HER2- : Hormone Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative, LHRH : Luteinising Hormone-Releasing Hormone, mBC : metastatic Breast Cancer, RCT: Randomised Controlled Trial, SmPC: Summary of Product Characteristics.
References
  1. Rugo HS, et al. Breast Cancer Res Treat. 2019;174:719–29.
  2. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
  3. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439. 
  4. Cristofanilli M, et al. ECJ 2018;104:21-31.
  5. Turner NC, et al. N Engl J Med 2018;379:1926–1936 including supplementary appendix.
PP-IBR-GBR-4088. February 2022

PALOMA-2 Trial

IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results

  • ​​​​​​​IBRANCE® PALOMA-2 Trial
  • Study Design
  • Efficacy Outcomes
  • Quality of Life Outcomes
  • Safety Profile

PALOMA-3 Trial

IBRANCE® + Fulvestrant (Ful) Clinical Trial Results

  • ​​​​​​​IBRANCE® PALOMA-3 Trial
  • Study Design
  • Efficacy Outcomes
  • Quality of Life Outcomes
  • Safety Profile

Header

This text is for block level content. P tags can go in here too

Safety

IBRANCE® safety information and outcomes

  • IBRANCE® Safety Profile
  • Neutropenia
  • Adverse Event Management

Indication

  • IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

Ask Pfizer

Connect virtually with a Pfizer representative to discuss promotional information on a selected range of products.

Book now

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?